The Most Spoken Article on eu-authorized-representative
EU Authorized Representative for Medical Devices and IVDs in Europe
For manufacturers based outside the European Union, bringing medical devices or in vitro diagnostic devices into the European market involves more than product quality, technical documentation and regulatory preparation. Before a device can be placed on the European market, the manufacturer must appoint an EU Authorized Representative who is physically located in the European Union and legally recognised as the manufacturer’s official representative. This role is essential under the Medical Device Regulation and the In Vitro Diagnostic Medical Device Regulation because regulators need a responsible local party who can communicate, provide documentation and support compliance activities when required. An eu-authorized-representative is far more than just a name printed on a label. The representative acts as the legal presence of a non-EU manufacturer and plays an important role in maintaining market access, regulatory confidence and post-market accountability.
Why an EU Authorized Representative Is Required
European regulations for medical devices aim to safeguard patients, healthcare providers and users by ensuring every product entering the market has a defined chain of responsibility. When a manufacturer is based outside the European Union, regulators cannot always deal with that manufacturer directly in the same practical way they would with a local company. This is where the EU Authorized Representative becomes necessary. The representative provides a formal local presence and serves as the official point of communication for Competent Authorities, Notified Bodies and other regulatory stakeholders.
Without appointing an authorised representative, a non-EU manufacturer cannot legally place medical devices or IVDs on the European market. This applies to a wide range of products, from simple low-risk devices to complex diagnostic technologies. This obligation applies before market entry, meaning the representative must be selected early in the compliance journey rather than as a last administrative step. For companies preparing for European distribution, selecting the right EU Authorized Representative for Medical Devices and IVDs can significantly influence registration readiness, document management and long-term regulatory stability.
The Written Mandate Between Manufacturer and Representative
The connection between the manufacturer and the EU Authorized Representative must be formalised through a written mandate. This mandate defines the tasks the representative is authorised to perform and confirms the obligations both parties must follow. It is a critical compliance record as it defines the scope of representation, responsibilities, communication roles and the actions required if compliance issues occur.
An unclear or weakly drafted mandate can cause uncertainty at critical moments, particularly during authority requests, inspections, complaint handling or corrective actions. A strong mandate should clearly describe how documents will be made available, how regulatory communication will be handled, how incident information will be shared and what happens if the manufacturer does not meet its duties. For this reason, the mandate should be prepared carefully and reviewed before device registration or market placement begins.
Label and Packaging Requirements
The name and address of the EU Authorized Representative must be displayed on the device label, packaging or associated product information in accordance with applicable regulations. This enables authorities, distributors, healthcare professionals and users to identify the local representative connected to the device. It also strengthens the representative’s role as the official European contact for a manufacturer based outside the European Union.
Accurate labelling is essential because incorrect or missing representative details can lead to compliance issues and possible delays in market access. Manufacturers must ensure that artwork, instructions, declarations and registration data are consistent before product release. If the representative is changed, labelling and registration details may also require timely and controlled updates.
Documentation Review and Availability
A key responsibility of an EU Authorized Representative for Medical Devices and IVDs is to ensure that essential compliance documents are available and correctly prepared. This involves confirming the existence of the EU Declaration of Conformity, ensuring technical documentation is complete and verifying that the appropriate conformity assessment route has been followed based on device type and risk classification.
The representative may also need to hold or have access to copies of technical documentation, declarations and Notified Body certificates. These records must remain accessible for inspection by Competent Authorities for the specified retention period after the last device is marketed. This makes document control a central part of the relationship between manufacturer and representative. Manufacturers should keep records updated and ensure the representative can respond promptly to regulatory requests.
Communication With Competent Authorities and Notified Bodies
The EU Authorized Representative acts as the official communication channel between the non-EU manufacturer and European regulatory authorities. If a Competent Authority requests information, samples, technical documentation or clarification, the representative is expected to support the response process. The representative may also liaise with Notified Bodies when necessary, particularly regarding certification, conformity assessments or corrective measures.
This communication function goes beyond simply passing messages. A dependable representative should understand regulatory requirements, maintain accurate records and ensure responses are delivered within required timelines. Late or incomplete replies can lead to serious consequences, including market limitations or additional regulatory scrutiny. Therefore, manufacturers should partner with a representative who has strong regulatory expertise and well-defined internal systems.
Post-Market Surveillance and Incident Support
Compliance for medical devices does not stop once the product reaches the market. After a device is in circulation, manufacturers must continuously monitor performance, complaints, incidents and safety indicators. The EU Authorized Representative has a role in supporting this post-market responsibility by passing complaints and incident information to the manufacturer without delay.
This is especially important when information comes from clinicians, patients, users, distributors or authorities. Timely reporting allows the manufacturer to determine whether investigation, reporting, field safety actions or corrective measures are required. A strong representative understands that post-market surveillance is not just paperwork. It plays a key role in patient safety, product enhancement and continued regulatory confidence.
Registration Responsibilities and EUDAMED
Under European regulatory systems, manufacturer and representative details must be registered as required. The EU Authorized Representative may assist with registering both manufacturer and representative data in EUDAMED. Accurate registration helps authorities identify responsible parties, review device information and maintain market oversight.
Manufacturers should gather complete company information, device details, certificates and declarations before starting registration. Any inconsistency between labels, declarations, technical files and registration records can create delays or compliance questions. The representative’s role helps ensure all required information is aligned and accessible when required.
When the Representative Must Take Action
An EU Authorized Representative also carries responsibilities if the manufacturer does not fulfil regulatory requirements. If serious non-compliance occurs and the manufacturer does not correct the issue, the representative may need to end the mandate and inform relevant authorities and the Notified Body where applicable. This responsibility highlights that the role extends beyond administrative tasks.
The representative holds legal responsibility and cannot overlook serious compliance breaches. Manufacturers should therefore view the representative as a regulatory partner rather than a passive provider. Clear communication, regular document updates and defined responsibilities help avoid misunderstandings and minimise risk throughout the product lifecycle.
Choosing the Right EU Authorized Representative
Selecting an EU Authorized Representative should be done with care. Manufacturers should look for regulatory competence, experience with medical devices and IVDs, document handling capability, clear response procedures and a strong understanding of European requirements. The representative should be able to support communication with authorities, maintain records and guide the manufacturer on practical compliance expectations.
Cost alone should not determine the choice. A weak representative can create delays, poor communication and unnecessary risk, while a capable representative can help maintain confidence throughout market entry and post-market activities. The correct selection provides non-EU manufacturers with a reliable European presence and enables smoother regulatory management.
Conclusion
An EU Authorized Representative is essential for non-EU manufacturers that want to place medical devices or IVDs on the European market. The role includes legal representation, documentation availability, authority communication, complaint handling, registration support and action in cases of serious non-compliance. Under the Medical Device Regulation and the In Vitro Diagnostic Medical Device Regulation, appointing an authorised representative is mandatory and must be done eu-authorized-representative before market entry. By selecting a capable EU Authorized Representative for Medical Devices and IVDs, manufacturers can enhance compliance, protect patient safety and establish a solid foundation for long-term European market access.